保诚推升级危疾产品 少於百人中有一人患癌
保诚公布,推出升级版旗舰产品「危疾加护保III」,为「危疾加护保II」的升级版,旨在提供完善的癌症及危疾保障,以满足本港客户不断演变的健康需要,特别是癌症、心脏病发作、中风以及肺炎这些本港最常见的致命疾病。
保诚首席客户及市场拓展总监吴诗雅引述统计指,2018年香港新增癌症个案达34,028宗,按年上升2.9%并创下历史新高,平均每日有93人确诊患上癌症。她指危疾保障对每个人而言都是关键的考虑,毕竟长期治疗往往对家庭财务带来沉重压力,面对持续升级的健康挑战,相关产品经优化後,能提供更切合客户需要的保障。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.